Comparative safety of sodium–glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis
Dawwas GK, Flory JH, Hennessy S et al.
Diabetes Care. 2022;dc212177
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Dawwas GK, Flory JH, Hennessy S et al.
Diabetes Care. 2022;dc212177
Leggi
Moss AC, Robert AJ, Yi-Frazier JP, et al.
Diabetes Care. 2022;dc211553
Leggi
Raverdy V, Cohen RV, Caiazzo R, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00005-5
Leggi
Cousin E, Duncan BB, Stein C, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(21)00349-1
Leggi
Kadowaki T, Isendahl J, Khalid U, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00008-0.
Leggi
Chairistanidou C, Karatzi K, Karaglani E, et al.
NMCD. Pub. online 8 February 2022
Leggi
Tonon F, Candido R, Toffoli B, et al.
NMCD. Pub. online 9 February 2022
Leggi
Hao Z, Sun Y, Li G, et al.
BMC Endocr Disord. 2022;22(1):37.
Leggi
Zhang R, Mamza JB, Morris T, et al.
BMC Med. 2022;20(1):63.
Leggi
Pradhan R, Patorno E, Tesfaye H, et al.
Am J Epidemiol. 2022;kwac021.
Leggi